A CITF-funded study, published in preprint and not yet peer-reviewed, introduced a data visualization method called RF-PHATE, which was able to generate low-dimensional visualizations highlighting relevant data relationships while disregarding extraneous factors.
A CITF-funded study, published in BMJ Open, offers yet more evidence that COVID-19 vaccines are safe and effective. The study looked at the initial two COVID-19 vaccine doses and found they were safe, well-tolerated, and highly immunogenic across a broad spectrum of vaccine recipients, including those working in public-facing environments.
A CITF-funded study, published in iScience, found that transmission between hosts leads to mutations that cause immune evasion (when the immune system does not recognize a virus and does not mount a fight). The study also offered more evidence that exposure to other seasonal human coronaviruses (hCoV) helps develop a better immune response to SARS-CoV-2.
A CITF-funded study, published in iScience, developed four spike-based vaccines against the SARS-CoV-2 virus and measured antibody and cellular responses. All four – one based on the wildtype (original strain), one based on Beta, one based on Delta and a trivalent vaccine combining all three – produced a strong neutralizing antibody response in an animal model against all SARS-CoV-2 variants, including against the Omicron variant.
A CITF-funded study, published in Vaccines, showed that vaccination with an original COVID-19 mRNA vaccine induces a stronger circulating IgA immune response to the wildtype SARS-CoV-2 strain than to the Omicron strains.
A CITF-funded study, published as a preprint and not yet peer-reviewed, found that individuals with two vaccine doses and an Omicron breakthrough infection produced higher salivary SARS-CoV-2 IgA antibodies against Spike and RBD than individuals with three vaccine doses and no breakthrough infection.
A CITF-supported study, published in preprint and not yet peer-reviewed, found that two doses of mRNA vaccine (Pfizer or Moderna) produce robust antibody responses three months post-vaccination in both children and adults. Additionally, hybrid immunity (immunity derived from the combination of SARS-CoV-2 infection and vaccination) conferred stronger immune responses in both age groups when compared to vaccination alone.
CITF-funded studies continue to monitor immune responses to SARS-CoV-2 variants and increases in hybrid immunity among Canadians.
A CITF-funded study, published in JCI Insight, showed that hybrid immunity (resulting from having both an infection and vaccination) confers greater protection against cell-to-cell spread of SARS-CoV-2 than vaccination alone.
A CITF-funded study that presented results at the CITF Scientific Meeting in Vancouver found that T cells are an important part of the immune response, working along with antibodies to respond effectively to SARS-CoV-2 infection.